Roberto Ortiz

4.2k total citations · 1 hit paper
17 papers, 1.0k citations indexed

About

Roberto Ortiz is a scholar working on Infectious Diseases, Epidemiology and Emergency Medicine. According to data from OpenAlex, Roberto Ortiz has authored 17 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 6 papers in Epidemiology and 5 papers in Emergency Medicine. Recurrent topics in Roberto Ortiz's work include HIV/AIDS drug development and treatment (10 papers), HIV-related health complications and treatments (5 papers) and HIV Research and Treatment (4 papers). Roberto Ortiz is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), HIV-related health complications and treatments (5 papers) and HIV Research and Treatment (4 papers). Roberto Ortiz collaborates with scholars based in United States, United Kingdom and Spain. Roberto Ortiz's co-authors include Jan van Lunzen, Michael S. Saag, Sherene Min, Tamio Fujiwara, Judith Feinberg, Julia Harris, Andrea Antinori, Jan Fehr, Clare Brennan and Bonaventura Clotet and has published in prestigious journals such as The Lancet, AIDS and Molecular Cancer Therapeutics.

In The Last Decade

Roberto Ortiz

13 papers receiving 999 citations

Hit Papers

Once-daily dolutegravir versus darunavir plus ritonavir i... 2014 2026 2018 2022 2014 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    2014 350 citations Bonaventura Clotet, Judith Feinberg et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roberto Ortiz United States 8 967 624 275 250 64 17 1.0k
Rosa Ruiz-Valderas Spain 12 342 0.4× 160 0.3× 189 0.7× 35 0.1× 46 0.7× 26 457
Apicha Mahanontharit Thailand 15 594 0.6× 432 0.7× 315 1.1× 144 0.6× 199 3.1× 23 754
José Valdez Madruga Brazil 7 775 0.8× 600 1.0× 181 0.7× 154 0.6× 58 0.9× 11 829
Winai Ratanasuwan Thailand 16 808 0.8× 594 1.0× 257 0.9× 144 0.6× 73 1.1× 38 957
Jan Fourie United States 10 882 0.9× 678 1.1× 149 0.5× 190 0.8× 62 1.0× 13 939
Minh Lê France 14 402 0.4× 186 0.3× 217 0.8× 50 0.2× 140 2.2× 53 644
Cindy Vavro United States 15 1.4k 1.4× 1.1k 1.8× 284 1.0× 308 1.2× 72 1.1× 26 1.5k
José Ramón Santos Spain 17 612 0.6× 487 0.8× 177 0.6× 192 0.8× 50 0.8× 40 796
Nicholaos Bellos United States 11 825 0.9× 621 1.0× 134 0.5× 312 1.2× 58 0.9× 15 936
Christopher Stone United States 10 672 0.7× 550 0.9× 147 0.5× 108 0.4× 40 0.6× 18 733

Countries citing papers authored by Roberto Ortiz

Since Specialization
Citations

This map shows the geographic impact of Roberto Ortiz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Ortiz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Ortiz more than expected).

Fields of papers citing papers by Roberto Ortiz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Ortiz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Ortiz. The network helps show where Roberto Ortiz may publish in the future.

Co-authorship network of co-authors of Roberto Ortiz

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Ortiz. A scholar is included among the top collaborators of Roberto Ortiz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Ortiz. Roberto Ortiz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Rojanasopondist, Pakdee, Cristina Fernández, Alice Li, et al.. (2025). Safety and Efficacy of Ustekinumab and Vedolizumab Among Older Adults with Inflammatory Bowel Disease. Digestive Diseases and Sciences. 71(2). 594–604.
2.
3.
Rolle, Charlotte-Paige, José Ramón Arribas, Roberto Ortiz, et al.. (2025). Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials. Open Forum Infectious Diseases. 12(3). ofaf135–ofaf135.
4.
Lee, Catherine, Ziyue Karen Jiang, Simon Planken, et al.. (2023). Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer. Molecular Cancer Therapeutics. 22(7). 891–900.
5.
Rolle, Charlotte-Paige, Mezgebe Berhe, Tulika Singh, et al.. (2023). Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks. Open Forum Infectious Diseases. 10(3). ofad101–ofad101. 11 indexed citations
6.
Rolle, Charlotte-Paige, Mezgebe Berhe, Tulika Singh, et al.. (2021). 75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study. Open Forum Infectious Diseases. 8(Supplement_1). S49–S49. 1 indexed citations
7.
Ortiz, Roberto, et al.. (2021). Adenomatoid Odontogenic Tumor: Case Report and Literature Review. 5(1). 2 indexed citations
8.
Rolle, Charlotte-Paige, Mezgebe Berhe, Tulika Singh, et al.. (2021). Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. AIDS. 35(12). 1957–1965. 34 indexed citations
9.
10.
Sax, Paul E., Andrew Zolopa, Indira Brar, et al.. (2014). Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(1). 52–58. 165 indexed citations
11.
Clotet, Bonaventura, Judith Feinberg, Jan van Lunzen, et al.. (2014). Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. The Lancet. 383(9936). 2222–2231. 350 indexed citations breakdown →
12.
13.
Yoo, Don C., et al.. (2012). Benign ovarian serous cystadenoma mimicking papillary thyroid carcinoma metastasis on I-131 SPECT/CT.. PubMed. 95(2). 57–9. 1 indexed citations
14.
Ortiz, Roberto, Edwin DeJesus, Homayoon Khanlou, et al.. (2008). Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 22(12). 1389–1397. 278 indexed citations
15.
16.
Trifilio, Steve, Roberto Ortiz, Gennethel Pennick, et al.. (2005). Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation. 35(5). 509–513. 143 indexed citations
17.
Ortiz, Roberto, Thomas G. Baffes, & Willis J. Potts. (1953). Gastro-intestinal bleeding in infants and children.. PubMed. 27(4). 301–6. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosa Ruiz-Valderas Breakdown of academic impact, for papers by Apicha Mahanontharit Breakdown of academic impact, for papers by José Valdez Madruga Breakdown of academic impact, for papers by Winai Ratanasuwan Breakdown of academic impact, for papers by Jan Fourie Breakdown of academic impact, for papers by Minh Lê Breakdown of academic impact, for papers by Cindy Vavro Breakdown of academic impact, for papers by José Ramón Santos Breakdown of academic impact, for papers by Nicholaos Bellos Breakdown of academic impact, for papers by Christopher Stone
Rankless by CCL
2026